An IQVIA CEO Offered $26.1 Million as Bookings Hit a Report $3.15 Billion

Chairman and CEO Ari Bousbib reported a sale of about 106,000 shares of IQVIA Holdings Inc. (NYSE:IQV) for whole proceeds of $26.1 million in an SEC Type 4 submitting.

Transaction abstract

Transaction worth based mostly on SEC Type 4 weighted common sale worth ($245.51); post-transaction worth based mostly on July 29, 2026 market shut ($247.56).

Key questions

• What was the construction of this disposition?
  The transaction was an exercise-and-sell of inventory appreciation rights expiring in February 2027, the place 106,279 shares have been offered at a weighted common worth of $245.51.

• How does this impression the insider’s whole fairness publicity?
  Whereas direct holdings have been lowered by 11%, the insider retains a complete helpful place of 1.4 million shares, together with vital oblique pursuits that remained unchanged.

• What’s the significance of the Orohena Belief holdings?
  Bousbib maintains oblique possession of 543,000 shares by the Orohena Belief, offering continued long-term publicity to the corporate’s valuation separate from direct govt compensation.

• How does the execution worth examine to latest market valuation?
  The shares have been offered at a weighted common worth of $245.51, representing a slender low cost to the $247.56 market shut on the July 29, 2026 transaction date.

Firm Overview

Firm Snapshot

• IQVIA gives refined analytical insights, superior know-how options, and complete medical analysis companies to the life sciences trade by three major working segments: Expertise & Analytics Options, Analysis & Improvement Options, and Contract Gross sales & Medical Options.

• The corporate generates income by a diversified enterprise mannequin that mixes information analytics, know-how platforms, medical trial companies, and gross sales drive outsourcing options for pharmaceutical, biotechnology, and medical gadget producers globally.

• IQVIA serves pharmaceutical firms, biotechnology corporations, medical gadget producers, and healthcare organizations throughout the Americas, Europe, Africa, and Asia-Pacific areas, positioning itself as a essential accomplice in drug growth and commercialization.

IQVIA Holdings Inc. is a premier world supplier of life sciences intelligence and companies working throughout a number of continents. The corporate maintains a aggressive benefit by its built-in platform combining proprietary information, superior analytics, and intensive medical analysis capabilities, enabling shoppers to optimize drug growth timelines and commercialization methods. With TTM income of $17.0 billion and a market capitalization of $38.8 billion, IQVIA has demonstrated sturdy market positioning and sustained development momentum.

What this transaction means for buyers

The rights behind this sale carried a February 2027 expiration, which is the element that explains the timing. Bousbib was changing inventory appreciation rights earlier than they lapsed, a deadline that has nothing to do together with his learn on the inventory. He offered a bit below the day’s shut and saved a 1.4 million share place, together with 543,000 shares within the Orohena Belief that did not transfer. Finally, a CEO cashing in expiring rights whereas leaving his long-term holdings intact is principally only a signal of calendar administration, not a sign in regards to the agency’s prospects.

The timing, in the meantime, does observe a standout quarter. This previous week, IQVIA reported that it grew second-quarter income 8.7% to $4.37 billion, lifted adjusted earnings per share 12.1% to $3.15, and posted document medical bookings of $3.15 billion, a 1.22 book-to-bill. It additionally raised full-year steerage to as a lot as $17.475 billion. Bousbib referred to as it “as clear 1 / 4” as he is seen in additional than twenty years of reporting earnings throughout firms. Money movement, nevertheless, carried out shy of expectations, and the inventory took a small hit after earnings however continues to be up for the yr.

For long-term buyers, it will be necessary to see how each the backlog and money movement evolve from right here. IQVIA has $34.2 billion in contracted work, with about $9.2 billion changing to income inside a yr, so the expansion is seen properly into 2027. Whether or not demand from biotech shoppers — and the way that interprets to money movement — shall be key in figuring out the agency’s trajectory.

Do you have to purchase inventory in Iqvia Holdings proper now?

Before you purchase inventory in Iqvia Holdings, contemplate this:

The Motley Idiot Inventory Advisor analyst crew simply recognized what they imagine are the 10 finest shares for buyers to purchase now… and Iqvia Holdings wasn’t one in every of them. The ten shares that made the reduce are constructed for long-term development and will produce monster returns within the coming years.

Think about when Netflix made this record on December 17, 2004… when you invested $1,000 on the time of our suggestion, you’d have $386,727!* Or when Nvidia made this record on April 15, 2005… when you invested $1,000 on the time of our suggestion, you’d have $1,232,139!*

That efficiency is why individuals hear. With a monitor document of beating the S&P 500 by 4x, Inventory Advisor provides a definite benefit. Do not miss the most recent high 10 record, obtainable with Inventory Advisor, and be part of an investing neighborhood constructed for the lengthy haul.

See the ten shares »

*Inventory Advisor returns as of August 2, 2026.

Jonathan Ponciano has no place in any of the shares talked about. The Motley Idiot has positions in and recommends Iqvia Holdings. The Motley Idiot has a disclosure coverage.

An IQVIA CEO Offered $26.1 Million as Bookings Hit a Report $3.15 Billion was initially revealed by The Motley Idiot